Someone I love very much – in fact, a family member I idolize – was recently diagnosed with Parkinson’s disease. We are all in shock, and some members of my family are very frightened.
But I made a decision. Instead of being frightened, I’m going on the attack. As transformational thinking lecturer (and "est" founder) Werner Hans Erhard advocates, I’m going to be "cause in the matter."
So I’ve given myself a mission... to do my part to help find a cure.
And it’s an opportune time...
Major diseases like Parkinson’s, Alzheimer’s, and diabetes have a new enemy: research initiatives that attack them from fantastic new angles – yielding new protocols and medicines that can stop these maladies in their tracks or even reverse their chilling effects.
I’m not talking about "old school" drug protocols or research. I’m referring to the new healthcare and research Disruptors that I've been watching – and that are everywhere.
A powerful confluence of catalysts is making this possible, including new science, new technologies, and even new policies at the U.S. Food and Drug Administration (FDA) such as a groundbreaking “Fast Track” designation that slashes the time it takes to get new drugs into the hands of the patients who need them.
My resolve to help fight Parkinson's – as well as the other terrible diseases I mentioned – has already gained me access to some rarefied circles. I’ve been asked to join the board of an extraordinary company whose partnering doctors head up the research units in their respective medical specialties at the top hospitals in the United States.
I’m also helping raise money for research – which includes making contributions myself.
The doctors I’m backing are leaning into the future in a big way. The head of the research-and-development company I’m involved with previously ran a giant pharmaceutical company. He’s now attacking the diseases his old pharma company treated with drugs by developing completely new protocols to stop diseases from spreading and eventually reverse the damage that they do.
I’m not permitted to reveal the name of the company I’m working with just yet.
But I will make this promise: Over time – as we crusade toward our goals of arresting the spread of the diseases we’re attacking and advance development of reversal protocols – I will be able to share some of what we’re learning, how trials are going, and how our success will benefit everyone.
Eventually, there may even be ways for you or your loved ones to get into trials (we’re not there yet, but getting closer) by participating directly through new healthcare Disruptor tools like iPads and iPhones.
Meanwhile, we can invest in the Disruptor players, a move that will have dual benefits. It will not only aid the eventual defeat of these dreaded diseases, but it will allow us to profit from the full-frontal assault on them.
About the Author
Shah Gilani boasts a financial pedigree unlike any other. He ran his first hedge fund in 1982 from his seat on the floor of the Chicago Board of Options Exchange. When options on the Standard & Poor's 100 began trading on March 11, 1983, Shah worked in "the pit" as a market maker.
The work he did laid the foundation for what would later become the VIX - to this day one of the most widely used indicators worldwide. After leaving Chicago to run the futures and options division of the British banking giant Lloyd's TSB, Shah moved up to Roosevelt & Cross Inc., an old-line New York boutique firm. There he originated and ran a packaged fixed-income trading desk, and established that company's "listed" and OTC trading desks.
Shah founded a second hedge fund in 1999, which he ran until 2003.
Shah's vast network of contacts includes the biggest players on Wall Street and in international finance. These contacts give him the real story - when others only get what the investment banks want them to see.
Today, as editor of Hyperdrive Portfolio, Shah presents his legion of subscribers with massive profit opportunities that result from paradigm shifts in the way we work, play, and live.
Shah is a frequent guest on CNBC, Forbes, and MarketWatch, and you can catch him every week on Fox Business's Varney & Co.